NEW YORK (GenomeWeb) – GenMark Diagnostics said today that it has increased the size of its previously announced public offering to 6,382,978 shares of its common stock price at $11.75 per share.

The gross proceeds to GenMark, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be about $75.0 million.

JP Morgan and Bank of America Merrill Lynch are joint book-running managers for the offering. William Blair, Cowen, and Raymond James are co-managers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.